Age-Related Macular Degeneration

Ophthalmology·MeSH: Macular Degeneration

Prevalence

2000.0 / 100K

Incidence

200.0 / 100K/yr

59 drugs in development·34 companies·4 clinical trials

Drug Pipeline by Phase

Approved(5)

Drug	Company
beovu	Apexigen, Inc. (APGN)
prednisolone	Amneal Pharmaceuticals, Inc. (AMRX)
prednisone	Amneal Pharmaceuticals, Inc. (AMRX)
SYFOVRE	Apellis Pharmaceuticals, Inc. (APLS)
vabysmo	XOMA Royalty Corporation (XOMA)

Phase 3(30)

Drug	Company
150 ivt	MOLECULAR PARTNERS AG (MOLN)
150 ivt	4D Molecular Therapeutics, Inc. (FDMT)
2.0 mg opt-302	Opthea Ltd (OPTEY)
4D-150	4D Molecular Therapeutics, Inc. (FDMT)
4D-150 IVT	4D Molecular Therapeutics, Inc. (FDMT)
4D-150 IVT	Merus N.V. (MRUS)
ABBV-RGX-314	REGENXBIO Inc. (RGNX)
abp 938	AMGEN INC (AMGN)
APL-2, Pegcetacoplan	Apellis Pharmaceuticals, Inc. (APLS)
APL-3007, pegcetacoplan	Apellis Pharmaceuticals, Inc. (APLS)
AXPAXLI	OCULAR THERAPEUTIX, INC (OCUL)
cemdisiran	West Pharmaceutical Services Inc. (WST)
cemdisiran	REGENERON PHARMACEUTICALS, INC. (REGN)
eylea	MOLECULAR PARTNERS AG (MOLN)
eylea	4D Molecular Therapeutics, Inc. (FDMT)
eylea	4D Molecular Therapeutics, Inc. (FDMT)
eylea	4D Molecular Therapeutics, Inc. (FDMT)
ixo-vec	Adverum Biotechnologies, Inc. (ADVM)
Ixo-vec (formerly ADVM-022)	Adverum Biotechnologies, Inc. (ADVM)
ixoberogene soroparvovec (Ixo-vec; formerly ADVM-022)	Adverum Biotechnologies, Inc. (ADVM)
ksi-501	Kodiak Sciences Inc. (KOD)
lx102	SAB BIOTHERAPEUTICS, INC. (SABS)
m710	MOMENTA PHARMACEUTICALS INC (MNTA)
OTX-TKI	OCULAR THERAPEUTIX, INC (OCUL)
Pegcetacoplan	Apellis Pharmaceuticals, Inc. (APLS)
Pemetrexed Disodium for Injection	ENANTA PHARMACEUTICALS INC (ENTA)
pozelimab	West Pharmaceutical Services Inc. (WST)
surabgene lomparvovec (sura-vec	REGENXBIO Inc. (RGNX)
tabirafusp tedromer	Kodiak Sciences Inc. (KOD)
tarcocimab tedromer	Kodiak Sciences Inc. (KOD)

Phase 2(9)

Drug	Company
ADX-038	ARS Pharmaceuticals, Inc. (SPRY)
ADX-246	Aldeyra Therapeutics, Inc. (ALDX)
ADX-631	Aldeyra Therapeutics, Inc. (ALDX)
APL-3007	Apellis Pharmaceuticals, Inc. (APLS)
CLS-AX	Clearside Biomedical, Inc. (CLSDQ)
fwy003	Novartis AG (NVS)
fwy003	NOVARTIS AG (NVSEF)
opregen	Lineage Cell Therapeutics, Inc. (LCTX)
th103	Kalaris Therapeutics, Inc. (KLRS)

Phase 1(4)

Drug	Company
4D-150 IVT	Crinetics Pharmaceuticals, Inc. (CRNX)
HiPSC-RPE cells	Amneal Pharmaceuticals, Inc. (AMRX)
lx102 subretinal	SAB BIOTHERAPEUTICS, INC. (SABS)
NK Cells	Amneal Pharmaceuticals, Inc. (AMRX)

Preclinical(5)

Drug	Company
agx51-α	ANGIOGENEX, INC. (AGGX)
agxa	ANGIOGENEX, INC. (AGGX)
dry amd gene therapy	APPLIED GENETIC TECHNOLOGIES CORP (AGTC)
inm-089	InMed Pharmaceuticals Inc. (INM)
szn-8141	Surrozen Inc. (SRZN)

BLA Filed(1)

Drug	Company
ons-5010/lytenava	Outlook Therapeutics, Inc. (OTLK)

Phase 1/Phase 2(3)

Phase 2/Phase 3(2)

Drug	Company
9mw0211	Apexigen, Inc. (APGN)
Surabgene Lomparvovec	AbbVie Inc. (ABBV)

BioSniper tracks 59 drugs in development for Age-Related Macular Degeneration across 34 companies.

There are 4 clinical trials targeting Age-Related Macular Degeneration tracked by BioSniper.

The estimated prevalence of Age-Related Macular Degeneration is approximately 2000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.